Workflow
DNA基因保存及孕环境检测服务
icon
Search documents
仟源医药:9月22日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-09-22 08:36
Company Overview - QianYuan Pharmaceutical (SZ 300254) announced on September 22 that its fifth board meeting was held via telecommunication to review the proposal for bank credit borrowing [1] - As of the report date, QianYuan Pharmaceutical has a market capitalization of 2.6 billion yuan [1] Revenue Composition - For the year 2024, the revenue composition of QianYuan Pharmaceutical is as follows: - Pharmaceutical manufacturing accounts for 96.68% - DNA gene preservation and prenatal environment testing services account for 1.93% - Health food accounts for 0.79% - Other businesses account for 0.51% - Commercial activities account for 0.1% [1]
仟源医药:9月15日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-09-15 08:48
截至发稿,仟源医药市值为27亿元。 每经头条(nbdtoutiao)——重大突破!中国这款新药,中美官方都认定有突破性疗效!世界肺癌大会 沸腾了 (记者 曾健辉) 每经AI快讯,仟源医药(SZ 300254,收盘价:10.97元)9月15日晚间发布公告称,公司第五届第三十 三次董事会会议于2025年9月15日以通讯表决的方式召开。会议审议了《关于公司开展融资租赁业务的 议案》等文件。 2024年1至12月份,仟源医药的营业收入构成为:医药制造占比96.68%,DNA基因保存及孕环境检测服 务占比1.93%,保健食品占比0.79%,其他业务占比0.51%,商业占比0.1%。 ...
仟源医药:董事、高级管理人员计划减持公司股份
Sou Hu Cai Jing· 2025-09-07 10:14
Group 1 - QianYuan Pharmaceutical announced that several executives plan to reduce their holdings in the company by a total of approximately 290,000 shares, which represents 0.1165% of the total share capital [1] - The company's revenue composition for the year 2024 is as follows: pharmaceutical manufacturing accounts for 96.68%, DNA gene preservation and prenatal environment testing services account for 1.93%, health food accounts for 0.79%, other businesses account for 0.51%, and commercial activities account for 0.1% [1] - As of the report, QianYuan Pharmaceutical has a market capitalization of 2.7 billion yuan [2]
仟源医药:8月8日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-08-08 11:04
Group 1 - The core point of the article is that QianYuan Pharmaceutical announced the convening of its 31st meeting of the 5th Board of Directors via communication voting on August 8, 2025, to discuss the proposal for the 4th extraordinary shareholders' meeting of 2025 [2] - For the year 2024, QianYuan Pharmaceutical's revenue composition is as follows: pharmaceutical manufacturing accounts for 96.68%, DNA gene preservation and prenatal environment testing services account for 1.93%, health food accounts for 0.79%, other businesses account for 0.51%, and commercial activities account for 0.1% [2]